• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Edesa Biotech Inc.

    6/26/26 5:05:26 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EDSA alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox not checkedNoneEntity Type
    0001540159
    Stellar Biotechnologies, Inc.
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     Edesa Biotech, Inc.
    Jurisdiction of Incorporation/Organization
    BRITISH COLUMBIA, CANADA 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     Edesa Biotech, Inc.
    Street Address 1Street Address 2
     100 SPY COURT
     
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     MARKHAM
     ONTARIO, CANADA
     
     L3R 5H6
     289-800-9600 




    3. Related Persons

    Last NameFirst NameMiddle Name
    MacDonald
    Sean
    Street Address 1Street Address 2
     100 Spy Court 
     
    CityState/Province/CountryZIP/Postal Code
     Markham
     ONTARIO, CANADA
     L3R 5H6
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Nijhawan
    Pardeep
    Street Address 1Street Address 2
     100 Spy Court 
     
    CityState/Province/CountryZIP/Postal Code
     Markham
     ONTARIO, CANADA
     L3R 5H6
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Sistilli
    Carlo
    Street Address 1Street Address 2
     100 Spy Court 
     
    CityState/Province/CountryZIP/Postal Code
     Markham
     ONTARIO, CANADA
     L3R 5H6
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Brooks
    Michael
    Street Address 1Street Address 2
     100 Spy Court 
     
    CityState/Province/CountryZIP/Postal Code
     Markham
     ONTARIO, CANADA
     L3R 5H6
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Weiler
    Peter
    Street Address 1Street Address 2
     100 Spy Court 
     
    CityState/Province/CountryZIP/Postal Code
     Markham
     ONTARIO, CANADA
     L3R 5H6
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Chypyha
    Joan
    Street Address 1Street Address 2
     100 Spy Court 
     
    CityState/Province/CountryZIP/Postal Code
     Markham
     ONTARIO, CANADA
     L3R 5H6
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Olson
    Charles
    Street Address 1Street Address 2
     100 Spy Court 
     
    CityState/Province/CountryZIP/Postal Code
     Markham
     ONTARIO, CANADA
     L3R 5H6
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Marshall
    Patrick
    Street Address 1Street Address 2
     100 Spy Court 
     
    CityState/Province/CountryZIP/Postal Code
     Markham
     ONTARIO, CANADA
     L3R 5H6
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Liu
    David
    Street Address 1Street Address 2
     100 Spy Court 
     
    CityState/Province/CountryZIP/Postal Code
     Markham
     ONTARIO, CANADA
     L3R 5H6
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-06-16
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox not checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button not checked Yes Radio button checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     
     
    (Associated) Broker or DealerCheckbox not checkedNone(Associated) Broker or Dealer CRD Number  Checkbox not checkedNone
     
     
    Street Address 1Street Address 2
     
     
    City State/Province/CountryZIP/Postal Code
     
     
     
    State(s) of Solicitation Checkbox not checkedAll States
     



    13. Offering and Sales Amounts
     
    Total Offering Amount $
    3500000
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    3499986
    USD
    Total Remaining to be Sold $
    14
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
      
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    4
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    0
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox checkedEstimate
    Clarification of Response (if Necessary)
    The proceeds from the offering will be used for working capital and general corporate purposes.

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    Edesa Biotech, Inc./s/ Peter WeilerPeter WeilerChief Financial Officer2026-06-26




    Get the next $EDSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EDSA

    DatePrice TargetRatingAnalyst
    12/20/2021$16.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on Edesa Biotech with a new price target

    HC Wainwright & Co. initiated coverage of Edesa Biotech with a rating of Buy and set a new price target of $16.00

    12/20/21 6:08:21 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nijhawan Pardeep bought $6,599 worth of shares (1,000 units at $6.60), increasing direct ownership by 0.16% to 628,813 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/10/26 5:02:16 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep bought $39,000 worth of shares (10,000 units at $3.90) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/6/26 5:01:15 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep bought $42,560 worth of shares (10,000 units at $4.26) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/5/26 5:01:11 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    SEC Filings

    View All

    SEC Form EFFECT filed by Edesa Biotech Inc.

    EFFECT - Edesa Biotech, Inc. (0001540159) (Filer)

    7/14/26 12:15:20 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Edesa Biotech Inc.

    424B3 - Edesa Biotech, Inc. (0001540159) (Filer)

    7/13/26 4:15:12 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Edesa Biotech Inc.

    S-3 - Edesa Biotech, Inc. (0001540159) (Filer)

    7/2/26 5:00:27 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

    TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $3.5 million to the Company, before deducting offering expenses payable by Edesa. The common shares were placed without an agent, underwriter, broker or dealer. Investors in the PIPE include Edesa's Chief Executive Officer and healthcare-focused investors. The PIPE is ex

    6/11/26 9:15:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

    Analyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also experiencing respiratory distressNew data and analysis to be presented today at the 63rd European Renal Association Congress TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and respiratory distress. The data, which expand upon previously reported Phase 3

    6/5/26 9:20:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

    Oral presentation at ERA Congress, the flagship European nephrology meetingCompany expects to present additional data TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it will present data on paridiprubart, its first-in-class anti-TLR4 antibody, at the 63rd European Renal Association (ERA) Congress, to be held June 3 – 6, 2026, in Glasgow, Scotland. The ERA Congress is one of the world's leading nephrology meetings, convening clinicians and researchers focused on kidney disease. Edesa's accepted oral presentation will feature

    5/19/26 9:15:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nijhawan Pardeep was granted 3,378 shares, increasing direct ownership by 0.38% to 888,062 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    7/2/26 5:05:48 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep was granted 153,550 shares, increasing direct ownership by 21% to 884,684 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    6/16/26 5:03:05 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep was granted 1,671 shares, increasing direct ownership by 0.23% to 731,134 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    6/1/26 5:00:12 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Leadership Updates

    Live Leadership Updates

    View All

    Edesa Biotech Announces Chief Financial Officer Transition

    TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

    4/4/25 4:15:46 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

    TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions."Stephen joins Edesa at an exciting time as we build on our regulatory and clinical achievements and set our sights on additional growth opportunities. He shares our disciplined, manage-like-owner

    6/27/23 8:15:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Appoints Strategy Expert to Board of Directors

    TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors."Ms. Chao's appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders," said Par Nijhawan, MD, Chief Executive Officer of Edesa.Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily

    3/29/22 9:00:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Edesa Biotech Inc.

    SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)

    11/1/24 8:50:52 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Edesa Biotech Inc.

    SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)

    6/3/24 4:10:38 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Edesa Biotech Inc. (Amendment)

    SC 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)

    1/29/24 4:29:02 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care